AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12236848 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract (255-285 mg, 900 micro g hypericin content)
Number of subjects: 12
Study 12236848 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 12
Study 12236848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10865914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FCA)
Number of subjects: 98
Study 10865914 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B/flucytosine (ABF)
Number of subjects: 98
Study 7671898 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone intravenously (n = 26)
Number of subjects: 50
Study 7671898 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (n = 24)
Number of subjects: 50
Study 1776540 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Habits Questionnaire
Number of subjects: 306
Study 1776540 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Questionnaire
Number of subjects: 306
Study 1776540 — intervention group
Group type: COMPARATOR
Intervention: Chart screening method
Number of subjects: 306
Study 1776540 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE screening
Number of subjects: 306
Study 1776540 — intervention group
Group type: COMPARATOR
Intervention: Correlation between CAGE and chart screening
Number of subjects: 306
Study 6781808 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 15 mg . HCl
Number of subjects: 12
Study 6781808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31562774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable gluconate chelated 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 2890
Study 27405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC) 750 mg/day, titrated up to 2250 mg/day
Number of subjects: 2309
Study 27405619 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC) 3 g/day, titrated to achieve serum P levels of 3.5-6.0 mg/dL
Number of subjects: 2309
Study 25265197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-conflict condition (Iowa Gambling Task with high loss frequency and high long-term outcome)
Number of subjects: 86
Study 25265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-conflict condition (Iowa Gambling Task with low loss frequency and high long-term outcome)
Number of subjects: 86
Study 23652489 — intervention group
Group type: COMPARATOR
Intervention: Physical activity > 7 hours/week
Number of subjects: 888
Study 23652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum triglycerides
Number of subjects: 888
Study 23652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference in the top quartile
Number of subjects: 888
Study 23652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference in the middle quartiles
Number of subjects: 888
Study 23652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of serum HDL
Number of subjects: 888
Study 23652489 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately elevated triglycerides
Number of subjects: 888
Study 21359925 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning acupuncture (PA)
Number of subjects: 80
Study 21359925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate acupuncture (IA)
Number of subjects: 80
Study 21359925 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture treatment (Group C)
Number of subjects: 80
Study 19699111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg daily for 30 days, then 100 mg every other day
Number of subjects: 23
Study 19699111 — intervention group
Group type: COMPARATOR
Intervention: Colchicine 0.5 mg 3 times daily
Number of subjects: 23
Study 19699111 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 pill 2 times daily
Number of subjects: 23
Study 17455139 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation with reduced tidal volumes
Number of subjects: 0
Study 17455139 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 0
Study 15559341 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11455733 — intervention group
Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 0
Study 11455733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9495416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine hydrochloride 1:200,000 epinephrine with sodium bicarbonate
Number of subjects: 38
Study 9495416 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine hydrochloride 1:200,000 epinephrine without sodium bicarbonate
Number of subjects: 38
Study 7799341 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (intermittent treatment, every Monday, Wednesday, and Friday)
Number of subjects: 76
Study 7799341 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (daily treatment)
Number of subjects: 76
Study 7799341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both daily and intermittent D-penicillamine treatments
Number of subjects: 76
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin)
Number of subjects: 81
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: VEPA-M (VEPA plus methotrexate)
Number of subjects: 81
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 81
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-risk group
Number of subjects: 81
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 81
Study 2899140 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor performance status (PS) and high lactate dehydrogenase (LDH) level
Number of subjects: 81
Study 31454502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.8 mL, 36 mg lidocaine HCl and 0.0225 mg epinephrine)
Number of subjects: 32
Study 31454502 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (1.8 mL, 50 mg tramadol HCl and 0.0225 mg epinephrine diluted to 1.8 mL by distilled water)
Number of subjects: 32
Study 31454502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 32
Study 30481895 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified skeletal maturity scoring (SSMS)
Number of subjects: 500
Study 30481895 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb ossification composite index (TOCI)
Number of subjects: 500
Study 28830404 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session group (30 min treadmill exercise, 3 days/week for 12 weeks)
Number of subjects: 36
Study 28830404 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-session group (3 sessions of 10 min exercise, 3 days/week for 12 weeks)
Number of subjects: 36
Study 28830404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 36
Study 25072444 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (adefovir 10 mg/d)
Number of subjects: 200
Study 25072444 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 200
Study 23632053 — intervention group
Group type: EXPERIMENTAL
Intervention: PIL approach (80 mg methylprednisolone)
Number of subjects: 37
Study 23632053 — intervention group
Group type: COMPARATOR
Intervention: MIL approach (80 mg methylprednisolone)
Number of subjects: 37
Study 23632053 — intervention group
Group type: EXPERIMENTAL
Intervention: PIL approach
Number of subjects: 37
Study 20430702 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (r‐rTMS)
Number of subjects: 23
Study 20430702 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (s‐rTMS)
Number of subjects: 23
Study 18086075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraOnce Laryngeal Mask
Number of subjects: 40
Study 18086075 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic
Number of subjects: 40
Study 16174713 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 infusion (4 pmol/kg x min)
Number of subjects: 6
Study 16174713 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (0.9%)
Number of subjects: 6
Study 12708955 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11061250 — intervention group
Group type: COMPARATOR
Intervention: NIH Stroke Scale (NIHSS) >17 plus atrial fibrillation
Number of subjects: 0
Study 11061250 — intervention group
Group type: COMPARATOR
Intervention: NIHSS >22 at 24 hours
Number of subjects: 0
Study 11061250 — intervention group
Group type: COMPARATOR
Intervention: NIHSS >16 at 7 to 10 days
Number of subjects: 0
Study 8902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline (2 ml solution diluted with 2 ml 0.9% saline for inhalation over 10 minutes)
Number of subjects: 90
Study 8902860 — intervention group
Group type: COMPARATOR
Intervention: Injected epinephrine (0.01 ml/kg of 1:1000 epinephrine, maximum 0.3 ml, subcutaneous injection)
Number of subjects: 90
Study 8902860 — intervention group
Group type: COMPARATOR
Intervention: Injected epinephrine (for patients with initial FEV1 lower than 60% of predicted value)
Number of subjects: 90
Study 8902860 — intervention group
Group type: COMPARATOR
Intervention: Injected epinephrine
Number of subjects: 90
Study 1867917 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 400 mg cimetidine
Number of subjects: 122
Study 1867917 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy with cimetidine
Number of subjects: 122
Study 1867917 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous maintenance therapy
Number of subjects: 122
Study 1867917 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy
Number of subjects: 122
Study 7003696 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 toothpaste
Number of subjects: 0
Study 7003696 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (no fluoride or stannous ions)
Number of subjects: 0
Study 30633334 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) 3 times per week for 50 weeks (20 weeks supervised, 30 weeks self-administered)
Number of subjects: 158
Study 30633334 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study 27866283 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback training (4-8 Hz for theta and 13-20 Hz for beta)
Number of subjects: 38
Study 27866283 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta/beta neurofeedback training
Number of subjects: 38
Study 25503447 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise (3 times per week for 12 weeks)
Number of subjects: 29
Study 25503447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 29
Study 23458393 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-IPL-PDT
Number of subjects: 41
Study 23458393 — intervention group
Group type: COMPARATOR
Intervention: IPL
Number of subjects: 41
Study 21368422 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic self-management education
Number of subjects: 248
Study 21368422 — intervention group
Group type: COMPARATOR
Intervention: Routine community education
Number of subjects: 248
Study 19548412 — intervention group
Group type: EXPERIMENTAL
Intervention: Breeze self‐adhesive resin cement
Number of subjects: 40
Study 19548412 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem self‐adhesive resin cement
Number of subjects: 40
Study 19548412 — intervention group
Group type: COMPARATOR
Intervention: Fuji glass‐ionomer cement
Number of subjects: 40
Study 19548412 — intervention group
Group type: COMPARATOR
Intervention: Fleck's zinc phosphate cement
Number of subjects: 40
Study 17822337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX; ≤1.8mg/kg per day)
Number of subjects: 142
Study 17822337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 17822337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 142
Study 15018291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.3 mg orally 7 hours prior to landing)
Number of subjects: 25
Study 15018291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 25
Study 11336591 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoporphin derivative (BPD) - verteporfin (Visudyne)
Number of subjects: 500000
Study 9716055 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen)
Number of subjects: 97
Study 9716055 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (identical treatment but with an additional high-dose regimen and peripheral-blood progenitor-cell support after the fourth FE120C course)
Number of subjects: 97
Study 7984328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta
Number of subjects: 0
Study 2721109 — intervention group
Group type: EXPERIMENTAL
Intervention: 337.5 mg/day propafenone
Number of subjects: 169
Study 2721109 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/day propafenone
Number of subjects: 169
Study 2721109 — intervention group
Group type: EXPERIMENTAL
Intervention: 675 mg/day propafenone
Number of subjects: 169
Study 2721109 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day propafenone
Number of subjects: 169
Study 2721109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 127471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 6-0787 combined with penicillin therapy
Number of subjects: 90
Study 127471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 6-0787 alone
Number of subjects: 90
Study 127471 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ro 6-0787-penicillin treatment
Number of subjects: 90
Study 127471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 6-0787
Number of subjects: 90
Study 31658975 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 501
Study 31658975 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL
Number of subjects: 501
Study 30357438 — intervention group
Group type: EXPERIMENTAL
Intervention: RGB-10 (biosimilar teriparatide)
Number of subjects: 54
Study 28344144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific tailored intervention
Number of subjects: 145
Study 28344144 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 145
Study 25923852 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (50 mg daily)
Number of subjects: 20
Study 25923852 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (50 mg weekly)
Number of subjects: 20
Study 23438932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 149
Study 23438932 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 149
Study 21305238 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school + exercise + physical treatment modalities
Number of subjects: 146
Study 21305238 — intervention group
Group type: COMPARATOR
Intervention: Exercise + physical treatment modalities
Number of subjects: 146
Study 19325134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 33690
Study 17702700 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered feedback combined with movement imagery
Number of subjects: 27
Study 17702700 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrostimulation
Number of subjects: 27
Study 15167505 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes, perceived partner approval, self-pride, parental pride
Number of subjects: 141
Study 15167505 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes, intentions to engage in sex in the next 3 months, self-pride, parental pride, goals, partner approval
Number of subjects: 141
Study 15167505 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes, subjective norms, self-efficacy, partner and parental approval, impulse control beliefs
Number of subjects: 141
Study 11820343 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist psychosexual counselling
Number of subjects: 36
Study 11820343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 9514451 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hemostatic puncture closure device
Number of subjects: 304
Study 9514451 — intervention group
Group type: COMPARATOR
Intervention: Manual pressure control group
Number of subjects: 304
Study 8000036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate-arginine salt (AGs)
Number of subjects: 3
Study 8000036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 3
Study 30620371 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg
Number of subjects: 440
Study 30620371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 30620371 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg
Number of subjects: 440
Study 29286586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Number of subjects: 54
Study 29286586 — intervention group
Group type: COMPARATOR
Intervention: Enriched supportive therapy (EST)
Number of subjects: 54
Study 27684809 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 75% solution
Number of subjects: 96
Study 27684809 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.2% diluted in glucose 70%
Number of subjects: 96
Study 24158271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) combined with best medical therapy (BMT)
Number of subjects: 0
Study 24158271 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT) alone
Number of subjects: 0
Study 22524590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0
Study 22524590 — intervention group
Group type: COMPARATOR
Intervention: Standard Blood Glucose Monitoring (BGM)
Number of subjects: 0
Study 19653746 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated stimulus-onset asynchrony (SOA) between successive items in the stream
Number of subjects: 0
Study 17447865 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 164
Study 17447865 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 164
Study 17447865 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 16291717 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (ethinyl estradiol 35 microg and varying doses of norgestimate: 0.18, 0.215, and 0.25 mg)
Number of subjects: 10
Study 16291717 — intervention group
Group type: COMPARATOR
Intervention: No triphasic oral contraceptive (control)
Number of subjects: 10
Study 16291717 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 10
Study 11896479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 6 mg apomorphine
Number of subjects: 44
Study 11896479 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 44
Study 11896479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 150 mg papaverine
Number of subjects: 44
Study 11896479 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 6 mg apomorphine + 150 mg papaverine
Number of subjects: 44
Study 11896479 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 44
Study 9695196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective individual matching procedure
Number of subjects: 0
Study 9695196 — intervention group
Group type: COMPARATOR
Intervention: Traditional randomized block design
Number of subjects: 0
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy (360‐700 MU/square meter of body surface, 2 or 3 times weekly for 12 to 24 weeks)
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher histological activity
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower percentage of HBcAg‐stained hepatocytes
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate amino transferase and alanine aminotransferase levels
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase peak prior to serum HBV‐DNA clearance
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of HBcAg stained cells with alanine aminotransferase levels
Number of subjects: 50
Study 7650334 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of HBcAg stained cells with histological activity index
Number of subjects: 50
Study 2516669 — intervention group
Group type: EXPERIMENTAL
Intervention: R/5 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 3 months)
Number of subjects: 503
Study 2516669 — intervention group
Group type: EXPERIMENTAL
Intervention: R/7 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 5 months)
Number of subjects: 503
Study 2516669 — intervention group
Group type: EXPERIMENTAL
Intervention: Z/7 (same regimen as R/7 but without rifampicin)
Number of subjects: 503
Study 2516669 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial drug resistance to streptomycin or isoniazid or both
Number of subjects: 503
Study 5023913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile fusidic acid gel introduced into the cavity on one occasion only
Number of subjects: 0
Study 5023913 — intervention group
Group type: COMPARATOR
Intervention: Daily superficial dressings impregnated with sodium fusidate ointment
Number of subjects: 0
Study 31858912 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 60
Study 31858912 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (Naproxen 1 gm/day or Etoricoxib 120 mg/day)
Number of subjects: 60
Study 30639273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination training (SEQ)
Number of subjects: 30